Everolimus for Cowden Syndrome

This trial tests everolimus to determine if it can safely enhance social abilities in individuals with PTEN Hamartoma Tumor Syndrome (PHTS), a genetic condition that may cause social difficulties. Everolimus, already approved for other conditions, is now under study for its effects on social functioning in PHTS. Half of the participants will begin with everolimus, while the other half will receive a placebo for the first six months; afterward, all participants will take everolimus for the final six months. Individuals diagnosed with PHTS who experience moderate social difficulties may be eligible to participate. As a Phase 2, Phase 3 trial, this study evaluates everolimus's effectiveness in a smaller group and represents the final step before FDA approval, offering participants a chance to contribute to important research.

You may need to stop certain medications to join this trial. Specifically, you cannot take medications with anti-mTOR activity or certain other drugs like cyclosporine or ketoconazole. Check with the study team to see if your current medications are allowed.

Research has shown that everolimus is generally well-tolerated by people with PTEN Hamartoma Tumor Syndrome (PHTS). In past studies, patients used everolimus without major problems. Although these studies didn't always focus on drug tolerance, some results indicated that most participants managed the treatment well. The FDA has already approved everolimus for other conditions, such as tuberous sclerosis complex and certain cancers, suggesting its safety for these uses and offering some reassurance for its safety in PHTS. However, like any medication, everolimus can have side effects, so discussing any concerns with a healthcare provider is important.¹²³⁴⁵

Unlike the standard treatment options for Cowden Syndrome, which often involve regular monitoring and surgical interventions, Everolimus offers a targeted approach by inhibiting mTOR, a protein that plays a key role in cell growth and proliferation. Researchers are excited about Everolimus because it specifically targets the genetic mutations associated with Cowden Syndrome, potentially reducing the risk of tumor development without invasive procedures. This oral medication is designed to achieve therapeutic blood levels gradually, allowing for a personalized treatment experience with the goal of improved outcomes for patients.

Research has shown that everolimus is generally safe for people with PTEN Hamartoma Tumor Syndrome (PHTS). However, earlier studies did not find major improvements in social skills. Some other areas, such as nonverbal IQ and verbal learning, showed positive changes. Everolimus already has approval for treating conditions like tuberous sclerosis complex, which is somewhat similar to PHTS. In this trial, participants will initially receive either everolimus or a placebo, followed by everolimus. While the main evidence for using everolimus in PHTS isn't strong, its safety and small improvements in certain areas suggest it might be helpful.⁴⁵⁶⁷⁸